Assessing Detection Algorithms for Insulin Pump Malfunctions in Type 1 Diabetes
NCT ID: NCT06147583
Last Updated: 2023-12-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
20 participants
INTERVENTIONAL
2023-12-31
2024-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer is:
"Are the proposed algorithms effective in detecting insulin suspension?" Effectiveness accounts for both high sensitivity (i.e. the fraction of suspension correctly detected) and low false alarm rate.
The study has three phases:
* free-living artificial pancreas data collection,
* in-patient induction of hyperglycemia (mimicking an insulin pump malfunction),
* retrospective analysis of the collected data to evaluate the effectiveness of the proposed algorithms in detecting insulin suspension.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
However, artificial pancreas systems can experience malfunctions, some of which are highly risky. The most dangerous malfunctions include insulin pump failures and infusion set occlusions, which lead to prolonged interruptions in insulin delivery. This exposes the patient to the risk of hyperglycemia and, even more dangerously, ketoacidosis, a severe complication that can result in hospitalization and, in severe cases, death. Unfortunately, patients do not always notice these issues in a timely manner.
This study aims to test new algorithms for detecting pump/infusion set malfunctions that result in reduced or interrupted insulin delivery. The study consists of three phases:
* Phase 1: Preliminary Data Collection (Free-living Data) In this phase, data related to glycemic trends and insulin administration in free-living conditions are collected. This data is obtained from a download form the patient's artificial pancreas. The one-month session is designed to gather a substantial amount of patient-specific data to enable the algorithms to learn how insulin and meals impact the patient's glycemia as recorded by the CGM sensor. During this phase, the patient continues to use their artificial pancreas in their daily life.
* Phase 2: Induction of Hyperglycemia The second phase involves the patient visiting the clinic, where, according to a specific protocol and a defined schedule, insulin infusion is temporarily suspended to simulate a pump malfunction. The resulting episode of hyperglycemia is closely monitored under medical supervision. At the end of the experiment, the study team assists the patient in restoring euglycemia before returning home.
* Phase 3: Retrospective Data Analysis In this phase, the collected data is retrospectively analyzed to evaluate the effectiveness of the proposed algorithms in detecting insulin suspension, simulating a pump malfunction. The sensitivity of the tested methods is assessed as the fraction of insulin suspensions (simulating a malfunction) correctly detected.
The uniqueness of this dataset lies in the controlled induction of malfunction, achieved by disconnecting the insulin pump and monitoring the resulting hyperglycemic episode. The presence of malfunctions in this data is certain and precisely characterized in terms of the start time and duration. The dataset resulting from this experimentation will be a valuable tool for the scientific community, enabling the retrospective testing of fault detection algorithms.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Insulin pump fault simulation
Collection of patients data during outpatient use of AID (automated insulin delivery); Inpatient simulation of insulin pump faults by suspension of insulin administration.
Simulation of an insulin pump failure
The intervention will consist in simulating an insulin pump failure by suspending insulin infusion and monitoring the consequent hyperglycemia.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Simulation of an insulin pump failure
The intervention will consist in simulating an insulin pump failure by suspending insulin infusion and monitoring the consequent hyperglycemia.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* At least 1 year from the diagnosis of type 1 diabetes mellitus
* Body mass index (BMI) less than 30 kg/m²
* Treated with automated insulin delivery system (AID) for at least 3 months
* Using carbohydrate counting to calculate meal bolus
* Glycated hemoglobin \< 10%
* If treated with antihypertensive, thyroid, antidepressant or lipid-lowering drugs, the therapy must be stable for at least 1 month before enrolment and remain stable for the entire duration of the study
* Awareness of the study design and purpose
* Willingness to undergo the study procedures
* Signing the informed consent
Exclusion Criteria
* Hematocrit less than 36% in females and less than 38% in males
* Presence of ischemic heart disease or congestive heart failure or history of a cerebrovascular event
* Therapy with a drug that significantly affects glucose metabolism (e.g. steroids)
* Uncontrolled hypertension
* Allergy or adverse reaction to insulin
* Known adrenal problems, pancreatic cancer, or insulinoma
* Any comorbid condition affecting glucose metabolism as judged by the investigator
* Current alcohol abuse, substance abuse, or serious mental illness, as judged by the investigator
* Unstable proliferative retinopathy according to fundus examination within the last year
* Known hemorrhagic diathesis or dyscrasia
* Blood donation in the last 3 months
* Renal failure with creatinine \> 150 μmol/L
* Impaired hepatic function based on plasma AST/ALT levels \> 2 times the upper limits of normal values
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azienda Ospedaliera di Padova
OTHER
University of Padova
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Daniela Bruttomesso
Principal Investigator and Medical Doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Azienda Ospedaliera di Padova
Padua, PD, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Daniela Bruttomesso, MD, PhD
Role: primary
Federico Boscari, MD, Phd
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Meneghetti L, Dassau E, Doyle FJ 3rd, Del Favero S. Machine Learning-Based Anomaly Detection Algorithms to Alert Patients Using Sensor Augmented Pump of Infusion Site Failures. J Diabetes Sci Technol. 2022 May;16(3):641-648. doi: 10.1177/1932296821997854. Epub 2021 Mar 9.
Meneghetti L, Facchinetti A, Favero SD. Model-Based Detection and Classification of Insulin Pump Faults and Missed Meal Announcements in Artificial Pancreas Systems for Type 1 Diabetes Therapy. IEEE Trans Biomed Eng. 2021 Jan;68(1):170-180. doi: 10.1109/TBME.2020.3004270. Epub 2020 Dec 21.
Meneghetti L, Susto GA, Del Favero S. Detection of Insulin Pump Malfunctioning to Improve Safety in Artificial Pancreas Using Unsupervised Algorithms. J Diabetes Sci Technol. 2019 Nov;13(6):1065-1076. doi: 10.1177/1932296819881452. Epub 2019 Oct 14.
Facchinetti A, Del Favero S, Sparacino G, Cobelli C. An online failure detection method of the glucose sensor-insulin pump system: improved overnight safety of type-1 diabetic subjects. IEEE Trans Biomed Eng. 2013 Feb;60(2):406-16. doi: 10.1109/TBME.2012.2227256. Epub 2012 Nov 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
5731/AO/23
Identifier Type: OTHER
Identifier Source: secondary_id
5731/AO/23
Identifier Type: -
Identifier Source: org_study_id